http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 23 Feb 2026 21:25:00 -0500 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++4++++++++++MeiraGTx+Holdings+plc+++++For%3A+Feb+21++Filed+by%3A+Zeldin+Robert+K/26045304.html si-local-file:///var/storage/secattach/20260223/26045304.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++MeiraGTx+Holdings+plc+++++For%3A+Feb+21++Filed+by%3A+Zeldin+Robert+K/26045304.html Mon, 23 Feb 2026 21:25:00 -0500 MGTX O.22666513 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++MeiraGTx+Holdings+plc+++++For%3A+Feb+21++Filed+by%3A+Zeldin+Robert+K/26045304.html si-local-file:///var/storage/secattach/20260223/26045304.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++MeiraGTx+Holdings+plc+++++For%3A+Feb+21++Filed+by%3A+Zeldin+Robert+K/26045304.html Mon, 23 Feb 2026 21:25:00 -0500 MGTX O.22666513 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++MeiraGTx+Holdings+plc+++++For%3A+Feb+21++Filed+by%3A+Wollin+Robert+J/26045302.html si-local-file:///var/storage/secattach/20260223/26045302.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++MeiraGTx+Holdings+plc+++++For%3A+Feb+21++Filed+by%3A+Wollin+Robert+J/26045302.html Mon, 23 Feb 2026 21:24:00 -0500 MGTX O.22666513 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++MeiraGTx+Holdings+plc+++++For%3A+Feb+21++Filed+by%3A+Wollin+Robert+J/26045302.html si-local-file:///var/storage/secattach/20260223/26045302.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++MeiraGTx+Holdings+plc+++++For%3A+Feb+21++Filed+by%3A+Wollin+Robert+J/26045302.html Mon, 23 Feb 2026 21:24:00 -0500 MGTX O.22666513 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++MeiraGTx+Holdings+plc+++++For%3A+Feb+21++Filed+by%3A+Naylor+Stuart/26045298.html si-local-file:///var/storage/secattach/20260223/26045298.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++MeiraGTx+Holdings+plc+++++For%3A+Feb+21++Filed+by%3A+Naylor+Stuart/26045298.html Mon, 23 Feb 2026 21:21:00 -0500 MGTX O.22666513 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++MeiraGTx+Holdings+plc+++++For%3A+Feb+21++Filed+by%3A+Naylor+Stuart/26045298.html si-local-file:///var/storage/secattach/20260223/26045298.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++MeiraGTx+Holdings+plc+++++For%3A+Feb+21++Filed+by%3A+Naylor+Stuart/26045298.html Mon, 23 Feb 2026 21:21:00 -0500 MGTX O.22666513 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++MeiraGTx+Holdings+plc+++++For%3A+Feb+21++Filed+by%3A+Giroux+Richard/26045297.html si-local-file:///var/storage/secattach/20260223/26045297.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++MeiraGTx+Holdings+plc+++++For%3A+Feb+21++Filed+by%3A+Giroux+Richard/26045297.html Mon, 23 Feb 2026 21:20:00 -0500 MGTX O.22666513 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++MeiraGTx+Holdings+plc+++++For%3A+Feb+21++Filed+by%3A+Giroux+Richard/26045297.html si-local-file:///var/storage/secattach/20260223/26045297.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++MeiraGTx+Holdings+plc+++++For%3A+Feb+21++Filed+by%3A+Giroux+Richard/26045297.html Mon, 23 Feb 2026 21:20:00 -0500 MGTX O.22666513 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++MeiraGTx+Holdings+plc+++++For%3A+Feb+21++Filed+by%3A+Forbes+Alexandria/26045291.html si-local-file:///var/storage/secattach/20260223/26045291.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++MeiraGTx+Holdings+plc+++++For%3A+Feb+21++Filed+by%3A+Forbes+Alexandria/26045291.html Mon, 23 Feb 2026 21:18:00 -0500 MGTX O.22666513 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++MeiraGTx+Holdings+plc+++++For%3A+Feb+21++Filed+by%3A+Forbes+Alexandria/26045291.html si-local-file:///var/storage/secattach/20260223/26045291.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++MeiraGTx+Holdings+plc+++++For%3A+Feb+21++Filed+by%3A+Forbes+Alexandria/26045291.html Mon, 23 Feb 2026 21:18:00 -0500 MGTX O.22666513 http://www.streetinsider.com/Press+Releases/Why+Late-Stage+CNS%2C+Oncology+Assets+Are+Becoming+the+Hottest+Targets+in+Biotech+M%26A/26006968.html <p>AUSTIN, Texas, Feb. 17, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=dpBu6oq_Nd2VjevOvLPx77l3kScoqmgDrKjdhZA10op98vDyDDJ4wnmCQRdqFId13ar4eHdP5XCTroYBCbgSx9m_4EE5C6kU1a4zk2lVvOU_F96FY53AfzsXXLfUkpLk4lmNgZBG45H0GGzmZB2l36K4qFZ__hpfbdhVhNVBRCw4ZhHXLqJyF6KmlYibx4FUe1dzYB23brH_QwY3kcl3gWb98TUyU7z1KBBYDVwmZrIxFmzLmJxPF4QeraayfQfRnThjct2Aovwhx_Xz3F5anZ491h2tyIDdrAY6Ux7ltw5ulA9m2t5nuoA2jnGZgsn2" rel="nofollow" target="_blank">BioMedWire Editorial Coverage</a>: Biotech dealmaking is increasingly defined by a clear strategic shift: Pharmaceutical companies are prioritizing de-risked, late-stage assets with human clinical validation rather than speculative early-stage programs. After years of capital flowing into preclinical platforms with uncertain timelines, investors and acquirers are gravitating toward programs with established safety and efficacy data that can accelerate commercialization pathways. This evolving landscape naturally places companies such as <strong>Oncotelic Therapeutics Inc. </strong>(OTCQB: OTLC) (<a href="https://www.globenewswire.com/Tracker?data=TJaLl-Hw-peffIbnbjET_Ol8CJWpC5grX_C7cWwPmHXWMuC5_n5dT1LH3rNNPclOXjZixayZXLKJm12bM0gV3n-P_din6ZvqrPCwyKb7uDYMTn-l2Xs4rUOmDBE4HTnv_d9_SCssWnOgqw3sME6iHw==" rel="nofollow" target="_blank">profile</a>), which holds multiple clinical-stage and late-stage programs across oncology and central nervous system http://www.streetinsider.com/Press+Releases/Why+Late-Stage+CNS%2C+Oncology+Assets+Are+Becoming+the+Hottest+Targets+in+Biotech+M%26A/26006968.html Tue, 17 Feb 2026 08:30:00 -0500 ARWR ARWR JNJ JNJ MGTX MGTX SUPN SUPN http://www.streetinsider.com/Press+Releases/Why+Late-Stage+CNS%2C+Oncology+Assets+Are+Becoming+the+Hottest+Targets+in+Biotech+M%26A/26006968.html <p>AUSTIN, Texas, Feb. 17, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=dpBu6oq_Nd2VjevOvLPx77l3kScoqmgDrKjdhZA10op98vDyDDJ4wnmCQRdqFId13ar4eHdP5XCTroYBCbgSx9m_4EE5C6kU1a4zk2lVvOU_F96FY53AfzsXXLfUkpLk4lmNgZBG45H0GGzmZB2l36K4qFZ__hpfbdhVhNVBRCw4ZhHXLqJyF6KmlYibx4FUe1dzYB23brH_QwY3kcl3gWb98TUyU7z1KBBYDVwmZrIxFmzLmJxPF4QeraayfQfRnThjct2Aovwhx_Xz3F5anZ491h2tyIDdrAY6Ux7ltw5ulA9m2t5nuoA2jnGZgsn2" rel="nofollow" target="_blank">BioMedWire Editorial Coverage</a>: Biotech dealmaking is increasingly defined by a clear strategic shift: Pharmaceutical companies are prioritizing de-risked, late-stage assets with human clinical validation rather than speculative early-stage programs. After years of capital flowing into preclinical platforms with uncertain timelines, investors and acquirers are gravitating toward programs with established safety and efficacy data that can accelerate commercialization pathways. This evolving landscape naturally places companies such as <strong>Oncotelic Therapeutics Inc. </strong>(OTCQB: OTLC) (<a href="https://www.globenewswire.com/Tracker?data=TJaLl-Hw-peffIbnbjET_Ol8CJWpC5grX_C7cWwPmHXWMuC5_n5dT1LH3rNNPclOXjZixayZXLKJm12bM0gV3n-P_din6ZvqrPCwyKb7uDYMTn-l2Xs4rUOmDBE4HTnv_d9_SCssWnOgqw3sME6iHw==" rel="nofollow" target="_blank">profile</a>), which holds multiple clinical-stage and late-stage programs across oncology and central nervous system http://www.streetinsider.com/Press+Releases/Why+Late-Stage+CNS%2C+Oncology+Assets+Are+Becoming+the+Hottest+Targets+in+Biotech+M%26A/26006968.html Tue, 17 Feb 2026 08:30:00 -0500 ARWR ARWR JNJ JNJ MGTX MGTX SUPN SUPN http://www.streetinsider.com/Press+Releases/Why+Late-Stage+CNS%2C+Oncology+Assets+Are+Becoming+the+Hottest+Targets+in+Biotech+M%26A/26006968.html <p>AUSTIN, Texas, Feb. 17, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=dpBu6oq_Nd2VjevOvLPx77l3kScoqmgDrKjdhZA10op98vDyDDJ4wnmCQRdqFId13ar4eHdP5XCTroYBCbgSx9m_4EE5C6kU1a4zk2lVvOU_F96FY53AfzsXXLfUkpLk4lmNgZBG45H0GGzmZB2l36K4qFZ__hpfbdhVhNVBRCw4ZhHXLqJyF6KmlYibx4FUe1dzYB23brH_QwY3kcl3gWb98TUyU7z1KBBYDVwmZrIxFmzLmJxPF4QeraayfQfRnThjct2Aovwhx_Xz3F5anZ491h2tyIDdrAY6Ux7ltw5ulA9m2t5nuoA2jnGZgsn2" rel="nofollow" target="_blank">BioMedWire Editorial Coverage</a>: Biotech dealmaking is increasingly defined by a clear strategic shift: Pharmaceutical companies are prioritizing de-risked, late-stage assets with human clinical validation rather than speculative early-stage programs. After years of capital flowing into preclinical platforms with uncertain timelines, investors and acquirers are gravitating toward programs with established safety and efficacy data that can accelerate commercialization pathways. This evolving landscape naturally places companies such as <strong>Oncotelic Therapeutics Inc. </strong>(OTCQB: OTLC) (<a href="https://www.globenewswire.com/Tracker?data=TJaLl-Hw-peffIbnbjET_Ol8CJWpC5grX_C7cWwPmHXWMuC5_n5dT1LH3rNNPclOXjZixayZXLKJm12bM0gV3n-P_din6ZvqrPCwyKb7uDYMTn-l2Xs4rUOmDBE4HTnv_d9_SCssWnOgqw3sME6iHw==" rel="nofollow" target="_blank">profile</a>), which holds multiple clinical-stage and late-stage programs across oncology and central nervous system http://www.streetinsider.com/Press+Releases/Why+Late-Stage+CNS%2C+Oncology+Assets+Are+Becoming+the+Hottest+Targets+in+Biotech+M%26A/26006968.html Tue, 17 Feb 2026 08:30:00 -0500 ARWR ARWR JNJ JNJ MGTX MGTX SUPN SUPN http://www.streetinsider.com/Press+Releases/Why+Late-Stage+CNS%2C+Oncology+Assets+Are+Becoming+the+Hottest+Targets+in+Biotech+M%26A/26006968.html <p>AUSTIN, Texas, Feb. 17, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=dpBu6oq_Nd2VjevOvLPx77l3kScoqmgDrKjdhZA10op98vDyDDJ4wnmCQRdqFId13ar4eHdP5XCTroYBCbgSx9m_4EE5C6kU1a4zk2lVvOU_F96FY53AfzsXXLfUkpLk4lmNgZBG45H0GGzmZB2l36K4qFZ__hpfbdhVhNVBRCw4ZhHXLqJyF6KmlYibx4FUe1dzYB23brH_QwY3kcl3gWb98TUyU7z1KBBYDVwmZrIxFmzLmJxPF4QeraayfQfRnThjct2Aovwhx_Xz3F5anZ491h2tyIDdrAY6Ux7ltw5ulA9m2t5nuoA2jnGZgsn2" rel="nofollow" target="_blank">BioMedWire Editorial Coverage</a>: Biotech dealmaking is increasingly defined by a clear strategic shift: Pharmaceutical companies are prioritizing de-risked, late-stage assets with human clinical validation rather than speculative early-stage programs. After years of capital flowing into preclinical platforms with uncertain timelines, investors and acquirers are gravitating toward programs with established safety and efficacy data that can accelerate commercialization pathways. This evolving landscape naturally places companies such as <strong>Oncotelic Therapeutics Inc. </strong>(OTCQB: OTLC) (<a href="https://www.globenewswire.com/Tracker?data=TJaLl-Hw-peffIbnbjET_Ol8CJWpC5grX_C7cWwPmHXWMuC5_n5dT1LH3rNNPclOXjZixayZXLKJm12bM0gV3n-P_din6ZvqrPCwyKb7uDYMTn-l2Xs4rUOmDBE4HTnv_d9_SCssWnOgqw3sME6iHw==" rel="nofollow" target="_blank">profile</a>), which holds multiple clinical-stage and late-stage programs across oncology and central nervous system http://www.streetinsider.com/Press+Releases/Why+Late-Stage+CNS%2C+Oncology+Assets+Are+Becoming+the+Hottest+Targets+in+Biotech+M%26A/26006968.html Tue, 17 Feb 2026 08:30:00 -0500 ARWR ARWR JNJ JNJ MGTX MGTX SUPN SUPN http://www.streetinsider.com/Press+Releases/Why+Late-Stage+CNS%2C+Oncology+Assets+Are+Becoming+the+Hottest+Targets+in+Biotech+M%26A/26006968.html <p>AUSTIN, Texas, Feb. 17, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=dpBu6oq_Nd2VjevOvLPx77l3kScoqmgDrKjdhZA10op98vDyDDJ4wnmCQRdqFId13ar4eHdP5XCTroYBCbgSx9m_4EE5C6kU1a4zk2lVvOU_F96FY53AfzsXXLfUkpLk4lmNgZBG45H0GGzmZB2l36K4qFZ__hpfbdhVhNVBRCw4ZhHXLqJyF6KmlYibx4FUe1dzYB23brH_QwY3kcl3gWb98TUyU7z1KBBYDVwmZrIxFmzLmJxPF4QeraayfQfRnThjct2Aovwhx_Xz3F5anZ491h2tyIDdrAY6Ux7ltw5ulA9m2t5nuoA2jnGZgsn2" rel="nofollow" target="_blank">BioMedWire Editorial Coverage</a>: Biotech dealmaking is increasingly defined by a clear strategic shift: Pharmaceutical companies are prioritizing de-risked, late-stage assets with human clinical validation rather than speculative early-stage programs. After years of capital flowing into preclinical platforms with uncertain timelines, investors and acquirers are gravitating toward programs with established safety and efficacy data that can accelerate commercialization pathways. This evolving landscape naturally places companies such as <strong>Oncotelic Therapeutics Inc. </strong>(OTCQB: OTLC) (<a href="https://www.globenewswire.com/Tracker?data=TJaLl-Hw-peffIbnbjET_Ol8CJWpC5grX_C7cWwPmHXWMuC5_n5dT1LH3rNNPclOXjZixayZXLKJm12bM0gV3n-P_din6ZvqrPCwyKb7uDYMTn-l2Xs4rUOmDBE4HTnv_d9_SCssWnOgqw3sME6iHw==" rel="nofollow" target="_blank">profile</a>), which holds multiple clinical-stage and late-stage programs across oncology and central nervous system http://www.streetinsider.com/Press+Releases/Why+Late-Stage+CNS%2C+Oncology+Assets+Are+Becoming+the+Hottest+Targets+in+Biotech+M%26A/26006968.html Tue, 17 Feb 2026 08:30:00 -0500 ARWR ARWR JNJ JNJ MGTX MGTX SUPN SUPN http://www.streetinsider.com/Press+Releases/Why+Late-Stage+CNS%2C+Oncology+Assets+Are+Becoming+the+Hottest+Targets+in+Biotech+M%26A/26006968.html <p>AUSTIN, Texas, Feb. 17, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=dpBu6oq_Nd2VjevOvLPx77l3kScoqmgDrKjdhZA10op98vDyDDJ4wnmCQRdqFId13ar4eHdP5XCTroYBCbgSx9m_4EE5C6kU1a4zk2lVvOU_F96FY53AfzsXXLfUkpLk4lmNgZBG45H0GGzmZB2l36K4qFZ__hpfbdhVhNVBRCw4ZhHXLqJyF6KmlYibx4FUe1dzYB23brH_QwY3kcl3gWb98TUyU7z1KBBYDVwmZrIxFmzLmJxPF4QeraayfQfRnThjct2Aovwhx_Xz3F5anZ491h2tyIDdrAY6Ux7ltw5ulA9m2t5nuoA2jnGZgsn2" rel="nofollow" target="_blank">BioMedWire Editorial Coverage</a>: Biotech dealmaking is increasingly defined by a clear strategic shift: Pharmaceutical companies are prioritizing de-risked, late-stage assets with human clinical validation rather than speculative early-stage programs. After years of capital flowing into preclinical platforms with uncertain timelines, investors and acquirers are gravitating toward programs with established safety and efficacy data that can accelerate commercialization pathways. This evolving landscape naturally places companies such as <strong>Oncotelic Therapeutics Inc. </strong>(OTCQB: OTLC) (<a href="https://www.globenewswire.com/Tracker?data=TJaLl-Hw-peffIbnbjET_Ol8CJWpC5grX_C7cWwPmHXWMuC5_n5dT1LH3rNNPclOXjZixayZXLKJm12bM0gV3n-P_din6ZvqrPCwyKb7uDYMTn-l2Xs4rUOmDBE4HTnv_d9_SCssWnOgqw3sME6iHw==" rel="nofollow" target="_blank">profile</a>), which holds multiple clinical-stage and late-stage programs across oncology and central nervous system http://www.streetinsider.com/Press+Releases/Why+Late-Stage+CNS%2C+Oncology+Assets+Are+Becoming+the+Hottest+Targets+in+Biotech+M%26A/26006968.html Tue, 17 Feb 2026 08:30:00 -0500 ARWR ARWR JNJ JNJ MGTX MGTX SUPN SUPN http://www.streetinsider.com/Press+Releases/Why+Late-Stage+CNS%2C+Oncology+Assets+Are+Becoming+the+Hottest+Targets+in+Biotech+M%26A/26006968.html <p>AUSTIN, Texas, Feb. 17, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=dpBu6oq_Nd2VjevOvLPx77l3kScoqmgDrKjdhZA10op98vDyDDJ4wnmCQRdqFId13ar4eHdP5XCTroYBCbgSx9m_4EE5C6kU1a4zk2lVvOU_F96FY53AfzsXXLfUkpLk4lmNgZBG45H0GGzmZB2l36K4qFZ__hpfbdhVhNVBRCw4ZhHXLqJyF6KmlYibx4FUe1dzYB23brH_QwY3kcl3gWb98TUyU7z1KBBYDVwmZrIxFmzLmJxPF4QeraayfQfRnThjct2Aovwhx_Xz3F5anZ491h2tyIDdrAY6Ux7ltw5ulA9m2t5nuoA2jnGZgsn2" rel="nofollow" target="_blank">BioMedWire Editorial Coverage</a>: Biotech dealmaking is increasingly defined by a clear strategic shift: Pharmaceutical companies are prioritizing de-risked, late-stage assets with human clinical validation rather than speculative early-stage programs. After years of capital flowing into preclinical platforms with uncertain timelines, investors and acquirers are gravitating toward programs with established safety and efficacy data that can accelerate commercialization pathways. This evolving landscape naturally places companies such as <strong>Oncotelic Therapeutics Inc. </strong>(OTCQB: OTLC) (<a href="https://www.globenewswire.com/Tracker?data=TJaLl-Hw-peffIbnbjET_Ol8CJWpC5grX_C7cWwPmHXWMuC5_n5dT1LH3rNNPclOXjZixayZXLKJm12bM0gV3n-P_din6ZvqrPCwyKb7uDYMTn-l2Xs4rUOmDBE4HTnv_d9_SCssWnOgqw3sME6iHw==" rel="nofollow" target="_blank">profile</a>), which holds multiple clinical-stage and late-stage programs across oncology and central nervous system http://www.streetinsider.com/Press+Releases/Why+Late-Stage+CNS%2C+Oncology+Assets+Are+Becoming+the+Hottest+Targets+in+Biotech+M%26A/26006968.html Tue, 17 Feb 2026 08:30:00 -0500 ARWR ARWR JNJ JNJ MGTX MGTX SUPN SUPN http://www.streetinsider.com/Press+Releases/Why+Late-Stage+CNS%2C+Oncology+Assets+Are+Becoming+the+Hottest+Targets+in+Biotech+M%26A/26006968.html <p>AUSTIN, Texas, Feb. 17, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=dpBu6oq_Nd2VjevOvLPx77l3kScoqmgDrKjdhZA10op98vDyDDJ4wnmCQRdqFId13ar4eHdP5XCTroYBCbgSx9m_4EE5C6kU1a4zk2lVvOU_F96FY53AfzsXXLfUkpLk4lmNgZBG45H0GGzmZB2l36K4qFZ__hpfbdhVhNVBRCw4ZhHXLqJyF6KmlYibx4FUe1dzYB23brH_QwY3kcl3gWb98TUyU7z1KBBYDVwmZrIxFmzLmJxPF4QeraayfQfRnThjct2Aovwhx_Xz3F5anZ491h2tyIDdrAY6Ux7ltw5ulA9m2t5nuoA2jnGZgsn2" rel="nofollow" target="_blank">BioMedWire Editorial Coverage</a>: Biotech dealmaking is increasingly defined by a clear strategic shift: Pharmaceutical companies are prioritizing de-risked, late-stage assets with human clinical validation rather than speculative early-stage programs. After years of capital flowing into preclinical platforms with uncertain timelines, investors and acquirers are gravitating toward programs with established safety and efficacy data that can accelerate commercialization pathways. This evolving landscape naturally places companies such as <strong>Oncotelic Therapeutics Inc. </strong>(OTCQB: OTLC) (<a href="https://www.globenewswire.com/Tracker?data=TJaLl-Hw-peffIbnbjET_Ol8CJWpC5grX_C7cWwPmHXWMuC5_n5dT1LH3rNNPclOXjZixayZXLKJm12bM0gV3n-P_din6ZvqrPCwyKb7uDYMTn-l2Xs4rUOmDBE4HTnv_d9_SCssWnOgqw3sME6iHw==" rel="nofollow" target="_blank">profile</a>), which holds multiple clinical-stage and late-stage programs across oncology and central nervous system http://www.streetinsider.com/Press+Releases/Why+Late-Stage+CNS%2C+Oncology+Assets+Are+Becoming+the+Hottest+Targets+in+Biotech+M%26A/26006968.html Tue, 17 Feb 2026 08:30:00 -0500 ARWR ARWR JNJ JNJ MGTX MGTX SUPN SUPN http://www.streetinsider.com/Globe+Newswire/Why+Late-Stage+CNS%2C+Oncology+Assets+Are+Becoming+the+Hottest+Targets+in+Biotech+M%26A/26006968.html <p>AUSTIN, Texas, Feb. 17, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=dpBu6oq_Nd2VjevOvLPx77l3kScoqmgDrKjdhZA10op98vDyDDJ4wnmCQRdqFId13ar4eHdP5XCTroYBCbgSx9m_4EE5C6kU1a4zk2lVvOU_F96FY53AfzsXXLfUkpLk4lmNgZBG45H0GGzmZB2l36K4qFZ__hpfbdhVhNVBRCw4ZhHXLqJyF6KmlYibx4FUe1dzYB23brH_QwY3kcl3gWb98TUyU7z1KBBYDVwmZrIxFmzLmJxPF4QeraayfQfRnThjct2Aovwhx_Xz3F5anZ491h2tyIDdrAY6Ux7ltw5ulA9m2t5nuoA2jnGZgsn2" rel="nofollow" target="_blank">BioMedWire Editorial Coverage</a>: Biotech dealmaking is increasingly defined by a clear strategic shift: Pharmaceutical companies are prioritizing de-risked, late-stage assets with human clinical validation rather than speculative early-stage programs. After years of capital flowing into preclinical platforms with uncertain timelines, investors and acquirers are gravitating toward programs with established safety and efficacy data that can accelerate commercialization pathways. This evolving landscape naturally places companies such as <strong>Oncotelic Therapeutics Inc. </strong>(OTCQB: OTLC) (<a href="https://www.globenewswire.com/Tracker?data=TJaLl-Hw-peffIbnbjET_Ol8CJWpC5grX_C7cWwPmHXWMuC5_n5dT1LH3rNNPclOXjZixayZXLKJm12bM0gV3n-P_din6ZvqrPCwyKb7uDYMTn-l2Xs4rUOmDBE4HTnv_d9_SCssWnOgqw3sME6iHw==" rel="nofollow" target="_blank">profile</a>), which holds multiple clinical-stage and late-stage programs across oncology and central nervous system http://www.streetinsider.com/Globe+Newswire/Why+Late-Stage+CNS%2C+Oncology+Assets+Are+Becoming+the+Hottest+Targets+in+Biotech+M%26A/26006968.html Tue, 17 Feb 2026 08:30:00 -0500 ARWR ARWR JNJ JNJ MGTX MGTX SUPN SUPN http://www.streetinsider.com/Globe+Newswire/Why+Late-Stage+CNS%2C+Oncology+Assets+Are+Becoming+the+Hottest+Targets+in+Biotech+M%26A/26006968.html <p>AUSTIN, Texas, Feb. 17, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=dpBu6oq_Nd2VjevOvLPx77l3kScoqmgDrKjdhZA10op98vDyDDJ4wnmCQRdqFId13ar4eHdP5XCTroYBCbgSx9m_4EE5C6kU1a4zk2lVvOU_F96FY53AfzsXXLfUkpLk4lmNgZBG45H0GGzmZB2l36K4qFZ__hpfbdhVhNVBRCw4ZhHXLqJyF6KmlYibx4FUe1dzYB23brH_QwY3kcl3gWb98TUyU7z1KBBYDVwmZrIxFmzLmJxPF4QeraayfQfRnThjct2Aovwhx_Xz3F5anZ491h2tyIDdrAY6Ux7ltw5ulA9m2t5nuoA2jnGZgsn2" rel="nofollow" target="_blank">BioMedWire Editorial Coverage</a>: Biotech dealmaking is increasingly defined by a clear strategic shift: Pharmaceutical companies are prioritizing de-risked, late-stage assets with human clinical validation rather than speculative early-stage programs. After years of capital flowing into preclinical platforms with uncertain timelines, investors and acquirers are gravitating toward programs with established safety and efficacy data that can accelerate commercialization pathways. This evolving landscape naturally places companies such as <strong>Oncotelic Therapeutics Inc. </strong>(OTCQB: OTLC) (<a href="https://www.globenewswire.com/Tracker?data=TJaLl-Hw-peffIbnbjET_Ol8CJWpC5grX_C7cWwPmHXWMuC5_n5dT1LH3rNNPclOXjZixayZXLKJm12bM0gV3n-P_din6ZvqrPCwyKb7uDYMTn-l2Xs4rUOmDBE4HTnv_d9_SCssWnOgqw3sME6iHw==" rel="nofollow" target="_blank">profile</a>), which holds multiple clinical-stage and late-stage programs across oncology and central nervous system http://www.streetinsider.com/Globe+Newswire/Why+Late-Stage+CNS%2C+Oncology+Assets+Are+Becoming+the+Hottest+Targets+in+Biotech+M%26A/26006968.html Tue, 17 Feb 2026 08:30:00 -0500 ARWR ARWR JNJ JNJ MGTX MGTX SUPN SUPN http://www.streetinsider.com/Globe+Newswire/Why+Late-Stage+CNS%2C+Oncology+Assets+Are+Becoming+the+Hottest+Targets+in+Biotech+M%26A/26006968.html <p>AUSTIN, Texas, Feb. 17, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=dpBu6oq_Nd2VjevOvLPx77l3kScoqmgDrKjdhZA10op98vDyDDJ4wnmCQRdqFId13ar4eHdP5XCTroYBCbgSx9m_4EE5C6kU1a4zk2lVvOU_F96FY53AfzsXXLfUkpLk4lmNgZBG45H0GGzmZB2l36K4qFZ__hpfbdhVhNVBRCw4ZhHXLqJyF6KmlYibx4FUe1dzYB23brH_QwY3kcl3gWb98TUyU7z1KBBYDVwmZrIxFmzLmJxPF4QeraayfQfRnThjct2Aovwhx_Xz3F5anZ491h2tyIDdrAY6Ux7ltw5ulA9m2t5nuoA2jnGZgsn2" rel="nofollow" target="_blank">BioMedWire Editorial Coverage</a>: Biotech dealmaking is increasingly defined by a clear strategic shift: Pharmaceutical companies are prioritizing de-risked, late-stage assets with human clinical validation rather than speculative early-stage programs. After years of capital flowing into preclinical platforms with uncertain timelines, investors and acquirers are gravitating toward programs with established safety and efficacy data that can accelerate commercialization pathways. This evolving landscape naturally places companies such as <strong>Oncotelic Therapeutics Inc. </strong>(OTCQB: OTLC) (<a href="https://www.globenewswire.com/Tracker?data=TJaLl-Hw-peffIbnbjET_Ol8CJWpC5grX_C7cWwPmHXWMuC5_n5dT1LH3rNNPclOXjZixayZXLKJm12bM0gV3n-P_din6ZvqrPCwyKb7uDYMTn-l2Xs4rUOmDBE4HTnv_d9_SCssWnOgqw3sME6iHw==" rel="nofollow" target="_blank">profile</a>), which holds multiple clinical-stage and late-stage programs across oncology and central nervous system http://www.streetinsider.com/Globe+Newswire/Why+Late-Stage+CNS%2C+Oncology+Assets+Are+Becoming+the+Hottest+Targets+in+Biotech+M%26A/26006968.html Tue, 17 Feb 2026 08:30:00 -0500 ARWR ARWR JNJ JNJ MGTX MGTX SUPN SUPN http://www.streetinsider.com/Globe+Newswire/Why+Late-Stage+CNS%2C+Oncology+Assets+Are+Becoming+the+Hottest+Targets+in+Biotech+M%26A/26006968.html <p>AUSTIN, Texas, Feb. 17, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=dpBu6oq_Nd2VjevOvLPx77l3kScoqmgDrKjdhZA10op98vDyDDJ4wnmCQRdqFId13ar4eHdP5XCTroYBCbgSx9m_4EE5C6kU1a4zk2lVvOU_F96FY53AfzsXXLfUkpLk4lmNgZBG45H0GGzmZB2l36K4qFZ__hpfbdhVhNVBRCw4ZhHXLqJyF6KmlYibx4FUe1dzYB23brH_QwY3kcl3gWb98TUyU7z1KBBYDVwmZrIxFmzLmJxPF4QeraayfQfRnThjct2Aovwhx_Xz3F5anZ491h2tyIDdrAY6Ux7ltw5ulA9m2t5nuoA2jnGZgsn2" rel="nofollow" target="_blank">BioMedWire Editorial Coverage</a>: Biotech dealmaking is increasingly defined by a clear strategic shift: Pharmaceutical companies are prioritizing de-risked, late-stage assets with human clinical validation rather than speculative early-stage programs. After years of capital flowing into preclinical platforms with uncertain timelines, investors and acquirers are gravitating toward programs with established safety and efficacy data that can accelerate commercialization pathways. This evolving landscape naturally places companies such as <strong>Oncotelic Therapeutics Inc. </strong>(OTCQB: OTLC) (<a href="https://www.globenewswire.com/Tracker?data=TJaLl-Hw-peffIbnbjET_Ol8CJWpC5grX_C7cWwPmHXWMuC5_n5dT1LH3rNNPclOXjZixayZXLKJm12bM0gV3n-P_din6ZvqrPCwyKb7uDYMTn-l2Xs4rUOmDBE4HTnv_d9_SCssWnOgqw3sME6iHw==" rel="nofollow" target="_blank">profile</a>), which holds multiple clinical-stage and late-stage programs across oncology and central nervous system http://www.streetinsider.com/Globe+Newswire/Why+Late-Stage+CNS%2C+Oncology+Assets+Are+Becoming+the+Hottest+Targets+in+Biotech+M%26A/26006968.html Tue, 17 Feb 2026 08:30:00 -0500 ARWR ARWR JNJ JNJ MGTX MGTX SUPN SUPN http://www.streetinsider.com/Globe+Newswire/Why+Late-Stage+CNS%2C+Oncology+Assets+Are+Becoming+the+Hottest+Targets+in+Biotech+M%26A/26006968.html <p>AUSTIN, Texas, Feb. 17, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=dpBu6oq_Nd2VjevOvLPx77l3kScoqmgDrKjdhZA10op98vDyDDJ4wnmCQRdqFId13ar4eHdP5XCTroYBCbgSx9m_4EE5C6kU1a4zk2lVvOU_F96FY53AfzsXXLfUkpLk4lmNgZBG45H0GGzmZB2l36K4qFZ__hpfbdhVhNVBRCw4ZhHXLqJyF6KmlYibx4FUe1dzYB23brH_QwY3kcl3gWb98TUyU7z1KBBYDVwmZrIxFmzLmJxPF4QeraayfQfRnThjct2Aovwhx_Xz3F5anZ491h2tyIDdrAY6Ux7ltw5ulA9m2t5nuoA2jnGZgsn2" rel="nofollow" target="_blank">BioMedWire Editorial Coverage</a>: Biotech dealmaking is increasingly defined by a clear strategic shift: Pharmaceutical companies are prioritizing de-risked, late-stage assets with human clinical validation rather than speculative early-stage programs. After years of capital flowing into preclinical platforms with uncertain timelines, investors and acquirers are gravitating toward programs with established safety and efficacy data that can accelerate commercialization pathways. This evolving landscape naturally places companies such as <strong>Oncotelic Therapeutics Inc. </strong>(OTCQB: OTLC) (<a href="https://www.globenewswire.com/Tracker?data=TJaLl-Hw-peffIbnbjET_Ol8CJWpC5grX_C7cWwPmHXWMuC5_n5dT1LH3rNNPclOXjZixayZXLKJm12bM0gV3n-P_din6ZvqrPCwyKb7uDYMTn-l2Xs4rUOmDBE4HTnv_d9_SCssWnOgqw3sME6iHw==" rel="nofollow" target="_blank">profile</a>), which holds multiple clinical-stage and late-stage programs across oncology and central nervous system http://www.streetinsider.com/Globe+Newswire/Why+Late-Stage+CNS%2C+Oncology+Assets+Are+Becoming+the+Hottest+Targets+in+Biotech+M%26A/26006968.html Tue, 17 Feb 2026 08:30:00 -0500 ARWR ARWR JNJ JNJ MGTX MGTX SUPN SUPN http://www.streetinsider.com/Globe+Newswire/Why+Late-Stage+CNS%2C+Oncology+Assets+Are+Becoming+the+Hottest+Targets+in+Biotech+M%26A/26006968.html <p>AUSTIN, Texas, Feb. 17, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=dpBu6oq_Nd2VjevOvLPx77l3kScoqmgDrKjdhZA10op98vDyDDJ4wnmCQRdqFId13ar4eHdP5XCTroYBCbgSx9m_4EE5C6kU1a4zk2lVvOU_F96FY53AfzsXXLfUkpLk4lmNgZBG45H0GGzmZB2l36K4qFZ__hpfbdhVhNVBRCw4ZhHXLqJyF6KmlYibx4FUe1dzYB23brH_QwY3kcl3gWb98TUyU7z1KBBYDVwmZrIxFmzLmJxPF4QeraayfQfRnThjct2Aovwhx_Xz3F5anZ491h2tyIDdrAY6Ux7ltw5ulA9m2t5nuoA2jnGZgsn2" rel="nofollow" target="_blank">BioMedWire Editorial Coverage</a>: Biotech dealmaking is increasingly defined by a clear strategic shift: Pharmaceutical companies are prioritizing de-risked, late-stage assets with human clinical validation rather than speculative early-stage programs. After years of capital flowing into preclinical platforms with uncertain timelines, investors and acquirers are gravitating toward programs with established safety and efficacy data that can accelerate commercialization pathways. This evolving landscape naturally places companies such as <strong>Oncotelic Therapeutics Inc. </strong>(OTCQB: OTLC) (<a href="https://www.globenewswire.com/Tracker?data=TJaLl-Hw-peffIbnbjET_Ol8CJWpC5grX_C7cWwPmHXWMuC5_n5dT1LH3rNNPclOXjZixayZXLKJm12bM0gV3n-P_din6ZvqrPCwyKb7uDYMTn-l2Xs4rUOmDBE4HTnv_d9_SCssWnOgqw3sME6iHw==" rel="nofollow" target="_blank">profile</a>), which holds multiple clinical-stage and late-stage programs across oncology and central nervous system http://www.streetinsider.com/Globe+Newswire/Why+Late-Stage+CNS%2C+Oncology+Assets+Are+Becoming+the+Hottest+Targets+in+Biotech+M%26A/26006968.html Tue, 17 Feb 2026 08:30:00 -0500 ARWR ARWR JNJ JNJ MGTX MGTX SUPN SUPN http://www.streetinsider.com/Globe+Newswire/Why+Late-Stage+CNS%2C+Oncology+Assets+Are+Becoming+the+Hottest+Targets+in+Biotech+M%26A/26006968.html <p>AUSTIN, Texas, Feb. 17, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=dpBu6oq_Nd2VjevOvLPx77l3kScoqmgDrKjdhZA10op98vDyDDJ4wnmCQRdqFId13ar4eHdP5XCTroYBCbgSx9m_4EE5C6kU1a4zk2lVvOU_F96FY53AfzsXXLfUkpLk4lmNgZBG45H0GGzmZB2l36K4qFZ__hpfbdhVhNVBRCw4ZhHXLqJyF6KmlYibx4FUe1dzYB23brH_QwY3kcl3gWb98TUyU7z1KBBYDVwmZrIxFmzLmJxPF4QeraayfQfRnThjct2Aovwhx_Xz3F5anZ491h2tyIDdrAY6Ux7ltw5ulA9m2t5nuoA2jnGZgsn2" rel="nofollow" target="_blank">BioMedWire Editorial Coverage</a>: Biotech dealmaking is increasingly defined by a clear strategic shift: Pharmaceutical companies are prioritizing de-risked, late-stage assets with human clinical validation rather than speculative early-stage programs. After years of capital flowing into preclinical platforms with uncertain timelines, investors and acquirers are gravitating toward programs with established safety and efficacy data that can accelerate commercialization pathways. This evolving landscape naturally places companies such as <strong>Oncotelic Therapeutics Inc. </strong>(OTCQB: OTLC) (<a href="https://www.globenewswire.com/Tracker?data=TJaLl-Hw-peffIbnbjET_Ol8CJWpC5grX_C7cWwPmHXWMuC5_n5dT1LH3rNNPclOXjZixayZXLKJm12bM0gV3n-P_din6ZvqrPCwyKb7uDYMTn-l2Xs4rUOmDBE4HTnv_d9_SCssWnOgqw3sME6iHw==" rel="nofollow" target="_blank">profile</a>), which holds multiple clinical-stage and late-stage programs across oncology and central nervous system http://www.streetinsider.com/Globe+Newswire/Why+Late-Stage+CNS%2C+Oncology+Assets+Are+Becoming+the+Hottest+Targets+in+Biotech+M%26A/26006968.html Tue, 17 Feb 2026 08:30:00 -0500 ARWR ARWR JNJ JNJ MGTX MGTX SUPN SUPN